Table 1.
Virus neutralization studies
| Plasma or Ab |
Clade B HIV-1 |
Clade A HIV-1 |
|||||||
|---|---|---|---|---|---|---|---|---|---|
| SF162 | BaL | 89.6 | dBR07 | aBL01 | 6101 | UG031 | RW020 | ||
| Patienta | IC50 | 255 | 220 | 261 | 553 | 90 | 105 | 187 | 32 |
| IC90 | 42 | 31 | 64 | 256 | 18 | 27 | 10 | 7 | |
| b12b | IC50 | 0.4 | 1.1 | 0.3 | 0.6 | 12 | >50 | >50 | >50 |
| IC90 | 2.7 | 12 | 5.5 | 22 | >50 | >50 | >50 | >50 | |
| 2F5 | IC50 | 2.9 | 1.1 | 0.1 | 1.1 | 3.1 | 50 | 9 | 0.3 |
| IC90 | >50 | >50 | 2 | >50 | >50 | >50 | >50 | 4 | |
| 2G12 | IC50 | 17 | 0.1 | >50 | >50 | >50 | 29 | >50 | 0.6 |
| IC90 | >50 | 10 | >50 | >50 | >50 | >50 | >50 | 5 | |
| HIVIG | IC50 | 40 | 320 | 13 | 140 | 685 | 850 | 5420 | 2004 |
| IC90 | 680 | 6590 | 430 | 2610 | >10000 | 8700 | >10000 | 6050 | |
a
IC50 and IC90 values of patient plasma neutralization are expressed as the reciprocal of plasma dilution required to inhibit 50 or 90%, respectively, of viral infection of CD8-depleted PBMC. The patient plasma was obtained in September, 2001 (see Supplementary Table 3).
b
IC50 and IC90 values of Env MAbs and HIVIG are expressed as the concentration (μg/ml) required to inhibit 50 or 90%, respectively, of viral infection of CD8-depleted PBMC.